ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.29
0.00%
US Tech 100
20,780.00
0.27%
S&P 500
5,994.57
-0.76%
US Dollar vs CAD
1.44205
-0.01%
Bitcoin
99,604.36
-1.79%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Anavex Life Sciences Corporation (AVXL) Share Price

Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

NASDAQ
8.64
-0.63
(-6.80%)
Closed February 03 3:00PM
Delayed by 15 minutes
8.64
0.00
( 0.00% )
Pre Market: 6:51AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
8.64
Bid
8.65
Ask
8.85
Volume
-
0.00 Day's Range 0.00
3.25 52 Week Range 14.4405
Market Cap
732.806M
Previous Close
8.64
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
1,912,490
Shares Outstanding
84,815,517
Dividend Yield
-
PE Ratio
-17.04
Earnings Per Share (EPS)
-0.51
Revenue
-
Net Profit
-43M

About Anavex Life Sciences Corporation

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.anavex.com
Headquarters
Carson City, Nevada, USA
Founded
-
Anavex Life Sciences Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AVXL. The last closing price for Anavex Life Sciences was US$8.64. Over the last year, Anavex Life Sciences shares have traded in a share price range of US$ 3.25 to US$ 14.4405.

Anavex Life Sciences currently has 84,815,517 shares outstanding. The market capitalization of Anavex Life Sciences is US$732.81 million. Anavex Life Sciences has a price to earnings ratio (PE ratio) of -17.04.

Ask ADVFN Intelligence (AI)

AVXL Latest News

More News

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

January 27 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

January 17 2025
Edgar (US Regulatory)

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and...

January 15 2025
GlobeNewswire Inc.

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of...

January 13 2025
GlobeNewswire Inc.

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

January 06 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

December 23 2024
Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

December 23 2024
Edgar (US Regulatory)

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

December 23 2024
GlobeNewswire Inc.

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

Blarcamesine: Potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Submission based on favorable ANAVEX®2-73-AD-004 trial results in...

December 23 2024
GlobeNewswire Inc.

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

December 16 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.325-13.29653788269.96510.058.4610726159.24875965CS
4-4.56-34.545454545513.214.258.46171107310.49808234CS
12-0.34-3.786191536758.9814.44057.18191249010.12491514CS
262.8348.70912220315.8114.44054.930113333928.74913709CS
522.9551.84534270655.6914.44053.2512909896.84647837CS
156-1.56-15.294117647110.215.243.2512063308.45728451CS
2605.34161.8181818183.331.52.2136331610.60259252CS

AVXL - Frequently Asked Questions (FAQ)

What is the current Anavex Life Sciences share price?
The current share price of Anavex Life Sciences is US$ 8.64
How many Anavex Life Sciences shares are in issue?
Anavex Life Sciences has 84,815,517 shares in issue
What is the market cap of Anavex Life Sciences?
The market capitalisation of Anavex Life Sciences is USD 732.81M
What is the 1 year trading range for Anavex Life Sciences share price?
Anavex Life Sciences has traded in the range of US$ 3.25 to US$ 14.4405 during the past year
What is the PE ratio of Anavex Life Sciences?
The price to earnings ratio of Anavex Life Sciences is -17.04
What is the reporting currency for Anavex Life Sciences?
Anavex Life Sciences reports financial results in USD
What is the latest annual profit for Anavex Life Sciences?
The latest annual profit of Anavex Life Sciences is USD -43M
What is the registered address of Anavex Life Sciences?
The registered address for Anavex Life Sciences is 701 S CARSON ST, STE 200, CARSON CITY, NEVADA, 89701
What is the Anavex Life Sciences website address?
The website address for Anavex Life Sciences is www.anavex.com
Which industry sector does Anavex Life Sciences operate in?
Anavex Life Sciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
QNTMQuantum Biopharma Ltd
US$ 6.46
(103.14%)
8.27M
EVAXEvaxion Biotech AS
US$ 3.86
(60.83%)
34.55M
PLTUDirexion DAily PLTR Bull 2X Shares
US$ 46.90
(42.16%)
196.25k
PTIRGraniteShares 2X Long PLTR Daily ETF
US$ 220.32
(41.85%)
131.7k
ACONAclarion Inc
US$ 9.28
(39.55%)
2.8M
UOKAMDJM Ltd
US$ 0.167
(-29.83%)
1.87M
TENXTenax Therapeutics Inc
US$ 4.48
(-24.71%)
98
EJHE Home Household Service Holdings Ltd
US$ 0.7928
(-22.27%)
61.93k
UPCUniverse Pharmaceuticals Inc
US$ 0.326
(-21.90%)
230.61k
GNSSGenasys Inc
US$ 2.39
(-21.90%)
1
EVAXEvaxion Biotech AS
US$ 3.86
(60.83%)
34.55M
IVVDInvivyd Inc
US$ 1.26
(18.87%)
19.51M
STISolidion Technology Inc
US$ 0.4111
(5.38%)
15.27M
LITMSnow Lake Resources Ltd
US$ 0.8238
(19.05%)
11.6M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0452
(-2.16%)
9.78M

AVXL Discussion

View Posts
ExtremelyBullishZig ExtremelyBullishZig 15 minutes ago
If you count where it closed. I could the "gap" between the candles. Just like you don't count the close or open when the gap fills you look to see that it touched it during the day. It went up to 5.85 that day and opened at 5.88 the next. But yes, regardless of how you define it...the gap is there.
👍️0
mike_dotcom mike_dotcom 41 minutes ago
No news today. I wonder how far down we'll go today?
👍️0
oldmystic oldmystic 6 hours ago
5.64 yes https://invst.ly/18qz13
👍️ 1
ExtremelyBullishZig ExtremelyBullishZig 9 hours ago
The gap is 5.85 on 11/30 and opened at 5.88. it was never filled. It is still there and easily found.

See you at 5.85. you seem to be missing 1 key bit of information...Anavex always drops. Anavex always lies.
👎️ 1 👺 1
ExtremelyBullishZig ExtremelyBullishZig 9 hours ago
There are other gaps. There is one at $5.85.
👎️ 1 👺 1
ExtremelyBullishZig ExtremelyBullishZig 9 hours ago
Are you being honest about this one?
👎️ 1 👺 1
aredrooster aredrooster 9 hours ago
8.64 yes
👍️0
williamssc williamssc 9 hours ago
TTTav66 posted on SS- Nice to see Anavex meeting recently with the Executive Director of Alzheimer Europe, Jean Georges, to discuss collaboration opportunities.
https://www.alzheimer-europe.org/sites/default/files/2025-02/2025-01_alzheimer_europe_newsletter.pdf

From page 7. 24 JANUARY Jean met with Anavex to discuss opportunities for collaboration in 2025

There is also a write-up of the JPAD article on pg. 16.
👍️ 8 👏 1 💯 2
kspar1 kspar1 10 hours ago
Missling must have a new media presence manager... Love it. Gotta stir the pot, beat that drum and establish that Anavex is an emergent presence to consider. He's on a LinkedIn roll.
https://www.linkedin.com/posts/christopher-missling-phd-18924a_the-rising-cost-of-drug-development-in-healthcare-activity-7292354207859310593-alCm?utm_source=share&utm_medium=member_android
👍️ 6
georgejjl georgejjl 12 hours ago
Expect Anavex Life Sciences To Report Fiscal 2025 First Quarter Financial Results and Provide Business Updates!!!

Good luck and GOD bless,
👍️0
Steady_T Steady_T 13 hours ago
Those questions are above my pay grade.

I have speculated that some short positions are still being held from the $30 peak and was repeatedly informed that shorts roll their positions often and those higher shorts would have long since been covered.

If I was shorting I would hold on to those high priced shorted shares since the large amount of money they provided is very well protected and those funds can be used to generate more income elsewhere. But then I don't short nor do I know anyone that does.
👍️0
kund kund 13 hours ago
Or maybe he just lied. He does that. Now you are talking. He has been lying and blabbering since 2015.
👍️ 1 👎️ 2 👺 2
mike_dotcom mike_dotcom 13 hours ago
Or maybe he just lied. He does that.
👎️ 2 👺 2
williamssc williamssc 14 hours ago
Good thinking as PD will likely to come up.
👍️ 2
Hoskuld Hoskuld 14 hours ago
We were told there would be a PD P3 trial update by the end of last month, so maybe that news is being saved for the upcoming conference call.
👍️ 3 🤷 1
poguemahone poguemahone 14 hours ago
We’re “oversold” but the price level can still fall to $6.70.

Makes sense.
👍️0
123tom 123tom 14 hours ago
If news remains a couple months away... I would maintain my cautious outlook for the bleeding down game to continue, maybe back into the 7's .How low can sellers take the price.the big upwave was a double. From 7.20 to 14.40. A Range pattern goes all the way back to the 7.25 support shoulder zone.
In my view, the upwave pattern needed to hold support around 9.50/10 area. Then around 9.00. But these failed. Now the picture starts to regain a downward bias ,neutral at best if 8 dollars holds .Below 8 dollars looks like a Range pattern forming. I hate the bleeding down game.
👎️ 1 👺 2 🥱 1
Kentucky123 Kentucky123 15 hours ago
The gap was filled and we are oversold. I still see the possibility of lower prices around the 6.70 level. The earnings call next week will probably see a retest of the low as Missling bashers come out in droves. Todays low did hit the midline of the Weekly Bollinger band and found support.
👍️ 3
LakeshoreLeo1953 LakeshoreLeo1953 15 hours ago
Come on George.
You MUST know the answer.
You Can Do IT.....
👎️ 1 👺 2
LakeshoreLeo1953 LakeshoreLeo1953 15 hours ago
What would be your guess (no way of confirming) of the
LOWEST priced borrowed share if indeed the shorts were
financing ALL of the roughly 25% of the floated shares?
Care to bracket it with an estimate of shares that were sold recently above say 13.50?
Seems Net to close the position today would be between $20M and $100M.

Don't hold me to those numbers, but it seems from today's close
AVXL would have to rise 40% with NO liquidation of short positions for
them to even consider pinching the sphincter.
👎️ 1 👺 2
LakeshoreLeo1953 LakeshoreLeo1953 15 hours ago
@ 8.64 ????
👺 2
Investor2014 Investor2014 16 hours ago
Never seems a safe bet.
👎️ 1 👺 2
Investor2014 Investor2014 16 hours ago
Let's see how you understand things come Feb'ish if there is no EMA approval. If there is approval, then my understanding would be that it is a good situation to be in with a gamble that paid off.
👺 2
georgejjl georgejjl 16 hours ago
Over 1.5 million shares of AVXL stock were bought today!!!

Good luck and GOD bless,
👍️0
sab63090 sab63090 16 hours ago
Citrati
Your mention of the $8.52 level was pretty darn accurate and I remember you mentioning it!...Good work.
👍️ 3
Steady_T Steady_T 16 hours ago
I have no opinion on that. It will happen when and if it happens. If I had to guess, I'd guess never. I think the shorts have an exit strategy. They have a lot of money to work with. Recently the short position was worth over $200 million. That value has increased with the SP drop. They could be squeezed if a huge partnership happened.

If a squeeze happens, I'll be all smiles.
👍️ 3
boi568 boi568 16 hours ago
But what you don't understand is, if that all came to pass, Investor would be attacking Missling for unnecessarily endangering the existence of the company by overspending on this one shot for success.
👍️ 4
Investor2014 Investor2014 16 hours ago
If there is a squeeze it would be Feb'ish 2026 on the assumption of an EMA approval.
Maybe, but I asked you.
Lot's of things, probably with exception of a $AVXL short squeeze, could happen in a year.

Ready to hear you own and Georgllj's assessment now, if you would please.
👎️ 2 👺 1
mike_dotcom mike_dotcom 16 hours ago
Just another schitty day. More to come.
👎️ 1 👺 1
Steady_T Steady_T 16 hours ago
Maybe, but I asked you.
👍️ 1
Investor2014 Investor2014 16 hours ago
Sounds like just the question for Georgellj.
👎️ 1 👺 1
gerry57 gerry57 16 hours ago
I have a question based on Investors position which is Anavex should have started a large p3 confirming trial or trials before applying for NDA with FDA. Doesn’t that position assume EMA denial? Missling has played a well thought out gambit in that had he started a p3 the fda could delay any decision pending trial results. The result would be 2 yrs more of shorting and speculation plus a capital cost to the company and a weak cash position. By applying to Europe first that scenario is off the table in the short term and possibly long term, well played imho.
👍️ 3
Steady_T Steady_T 16 hours ago
I see that 138,173 sh trade. My guess is that is a report from pool trade.
👍️ 1
Steady_T Steady_T 16 hours ago
If it could be predicted it wouldn't be a squeeze would it?
👍️ 4
aredrooster aredrooster 17 hours ago
How does a 100k + buy move the price down? Is that what my schwab is showing or is my chart wrong?
👍️ 1
sab63090 sab63090 17 hours ago
Tom, Kentucky, and OldMystic!

Congrats to you three guys! you all noticed the open gap in the 8 area and called it, even with OldMystic's recent change; it was listed on his model at one point.

Now EBZ has still been calling for the other open gap to be filled in the $5 plus area but missed the terrific run up to above $14, it goes back to November.

I did not want to overwhelm this message board from a certain person who said I was "clogging up the board"...although he might beat me on posts! Ha ha.

FWIW....it's the close that matters and those who bought this morning in solid stocks have probably taken a quick profit from the lows...it's never smart to get on the same side of the boat as everyone else.
👍️ 1 👎️ 1 👺 2 🫡 1
Investor2014 Investor2014 17 hours ago
Can't believe my luck - looks like $AVXL will lose less than 10% today, amazing!
👍️0
LakeshoreLeo1953 LakeshoreLeo1953 18 hours ago
I would just like to know….

If my personal allocation maxxed out
with a fill @ 14:05

Must I be counted as LONG/WGT
or
May I remain a trader trying to make the best of a bad re entry?

I’d love $1.50 from here unload and rethink.
Not sure Macro will allow and stock specific NEWS
remains a couple months away no matter what George claims.
👎️ 1 👺 2
boi568 boi568 19 hours ago
Actually, it's up to 28 percent as of the last report.
👍️0
IhidfromtheX IhidfromtheX 19 hours ago
Have short squeeze take the place of longer...
👍️0
123tom 123tom 19 hours ago
Zig... 5.80/5.50/5.00 is on the map, of course.... but I have to watch the pattern develop along the way.watching the tumble, and how strong the bounce is, or not, watching volume, watching news, etc... not just patterns. I do like patterns. Fibonacci math targets, and other tools to use. I always end up buying some shares "too soon" along the way down, and sometimes I miss the bottom because I expected another lower target that never came. And sometimes the price action does exactly what I anticipated. Right now, I'm watching the bounce today jumped up from 8.50 back to 9.10... not too bad. Let's see if 8.70/8.60 Holds strong and a rally can recover to target 9.80/10.00 area. That kind of recovery would suggest the bottom could be finished at 8.46. We'll see what plays out now.
Conversely, Bearish bias for lower downwaves ... might see 9.00 get capped and sellers aiming to target 8 dollars. My stink bids got filled at 8.60 today. I'll place another at 8.07 just for fun.( All my bids are very small shares. I don't like buying alot, too soon.) I end up having to sell them at b/e later.
👎️ 1 👺 2
kund kund 19 hours ago
Why no earning PR? Last year earning was on Feb7, and PRd week ahead.
👍️0
crescentmotor crescentmotor 19 hours ago
When is that promised short squeeze?

There is no reason to expect an AVXL short squeeze any time soon with low volume and 24% of the float held in short positions.
👍️0
Investor2014 Investor2014 20 hours ago
When is that promised short squeeze?
👎️ 1 👺 2
123tom 123tom 20 hours ago
I loved motorcycle riding. In rain was not as fun, for sure.
My chartwatching looks at support/resistance targets, and using the basic tools. 17 years experience, I try to buy the bottoms and sell the tops. My latest "forecast" was looking at one more dollar down, from 9.40 area to 8.45 area. Today we got it. I'd call that a bullseye. I hope folks interested in adding to their position, had their stink bids filled. Bottom fishing/bargain shopping. Could this sell down continue to 8.00 and into the 7's... I'm not prepared to see 8.00 fail just yet. But the major Shoulder zone is at 7.20/7.50, and below that, the shoulder around 5.00/5.50. And you can see the various pivot bounces along the way up from 5.00 to 9 . For bullish pattern on the big chart, I really want to see 8 dollars hold.
👍️ 1 👎️ 1 👺 2 😂 1 🥱 1
williamssc williamssc 20 hours ago
This is not ANVS.
👍️ 4
mrplmer mrplmer 20 hours ago
25M worth of dilution coming soon to a theatre near you soon
👍️ 1 👎️ 3 👺 3
LakeshoreLeo1953 LakeshoreLeo1953 21 hours ago
THAT is your Forex play?
How will you execute?
Bi lateral or a specific currency position?
Dry Powder?

IF we are talking gambling....
I preferred 10:57:53 for a third bite.
Still upside down, but 9.60ish basis.
👎️ 1 👺 2
LakeshoreLeo1953 LakeshoreLeo1953 21 hours ago
Go Back to Sleep. Let your bot takeover.
🎯 2 👍️ 2 👎️ 1 👺 2
Good Ole Bill Good Ole Bill 22 hours ago
Yes, and I'm sure
this gives you the tinglies in your naughty parts.
https://external-content.duckduckgo.com/iu/?u=https%3A%2F%2Ftse1.mm.bing.net%2Fth%3Fid%3DOIP.mGQ9YLwiLM-bdMR1hMtq8QAAAA%26pid%3DApi&f=1&ipt=8378b11ee20cc94b818cfd829dd7d974a281cccaa57219b59878ce3323034792&ipo=images

I'm still waiting and expect to be rich.

Bill
👍️ 1

Your Recent History

NASDAQ
AVXL
Anavex Life Sciences
BOV
MRFG3T
MARFRIG
BIT
UC92T7
Unicredit Bank
BIT
S28199
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads